Abstract 3301
Background
Different therapeutic options have been approved in the last decade for the management of mCRPC. New prognosis biomarkers are necessary in the clinical practice to determine the optimal treatment sequence. In recent years, a number of studies have suggested an association between SNPs in androgen related-genes and outcome.
Methods
Abi or Enza-treated mCRPC patients (pts) in the PROREPAIR-B study (NCT03075735) were included. Nine SNPs within the six candidate genes, namely, CYP17A1 (rs2486758), SCLO2B1 (rs1077858), SRD5A1 (rs3736316 and rs3822430), SRD5A2 (rs2300700), HSD3B1 (rs1047303) and SULT1E1 (rs10019305, rs4149534 and rs3775777) were genotyped. Genotyping was performed using predesigned and custom Taqman SNP genotyping assays (Applied Biosystems, Foster City, CA) and 7500 Fast Real-Time PCR systems (Applied Biosystems, Foster City, CA). The allele calls were identified by specific software. Associations between genotypes and overall survival (OS), time to PSA progression (TTPP) and time to castration resistance (TCR) were calculated with bivariate Cox-regression models including line of treatment. Kaplan Meier estimates of survival were calculated.
Results
322 pts treated with Abi (n = 259; 80.4%) or Enza (n = 63; 19.6%) were included in the analysis. Pts received Abi/Enza as first (n = 209; 64.9%), second (n = 111; 34.5%) or third (n = 2; 0.6%) line. Median OS was 25.9 m (95% CI: 23.5-28.3); median TTPP was 7 m (95% CI: 6.1-7.9) and median TCR was 29.1 m (95% CI: 24.1-34.1). rs3822430 SRD5A1 (0.82 [95% CI: 0.72-0.95]; p = 0.007) an rs3736316 SRD5A1 (HR: 0.86 [0.74-0.99]; p = 0.033) showed a significant association with OS. rs2486758 CYP17A1 (HR: 0.78 [0.64-0.95]; p = 0.014) showed a significant association with TCR. No SNPs showed an association with TTPP.
Conclusions
In our series (PROREPAIR-B) not significant associations were observed between most of the evaluated SNPs and outcomes in mCRPC patients treated with Abi or Enza.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centro Nacional de Investigaciones Oncológicas (CNIO).
Funding
Has not received any funding.
Disclosure
D. Lorente: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen-Cilag; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas Pharma; Travel / Accommodation / Expenses: Celgene. R. Lozano Mejorada: Speaker Bureau / Expert testimony, Research grant / Funding (institution): Roche; Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen-Cilag; Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: Astellas-Pharma. N. Romero Laorden: Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas-Pharma; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen-Cilag; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi-Aventis; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: PharmaMar; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche. A. Medina Colmenero: Honoraria (self), Travel / Accommodation / Expenses: Janssen-Cilag; Honoraria (self): Merck; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Janssen-Cilag; Travel / Accommodation / Expenses: Sanofi; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Novartis. J. Puente: Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Research grant / Funding (self): Astellas; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen-Cilag; Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Speaker Bureau / Expert testimony: Novartis; Speaker Bureau / Expert testimony: Lilly; Speaker Bureau / Expert testimony: Pierre Fabre; Speaker Bureau / Expert testimony: Celgene; Advisory / Consultancy: Kiowa; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Clovis Oncology; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Eisai; Advisory / Consultancy: Eusa Pharma; Advisory / Consultancy: Boehringer Ingelheim. R. Villatoro: Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas-Pharma; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Ipsen; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bristol. S. Vazquez Estevez: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy: MSD Oncology; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy: Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim. J.M. Piulats: Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen Oncology; Advisory / Consultancy: Astella Pharma; Advisory / Consultancy: VCN Biosciences; Advisory / Consultancy, Research grant / Funding (self): Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Clovis Oncology; Research grant / Funding (self): Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Research grant / Funding (self): Incyte; Research grant / Funding (self): MedImmune; Research grant / Funding (self): EMD Serono; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Bristol-Myers Squibb. N. Lainez: Advisory / Consultancy: Astellas-Pharma; Advisory / Consultancy: Roche; Advisory / Consultancy: MSD Oncology; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: BMS; Advisory / Consultancy: Pfizer. A. González del Alba: Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Astellas-Pharma; Advisory / Consultancy: Sanofi; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen Oncology; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: MSD Oncology; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Novartis; Advisory / Consultancy: Bayer; Advisory / Consultancy: Roche; Advisory / Consultancy: EUSA Pharma; Advisory / Consultancy: Ipsen; Full / Part-time employment: SERMAS. D. Olmos Hidalgo: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen; Honoraria (self): Sanofi; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Clovis Oncology; Travel / Accommodation / Expenses: Ipsen; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Tokai Pharmaceuticals. E. Castro: Honoraria (self), Travel / Accommodation / Expenses: Astellas-Pharma; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: Roche; Honoraria (self), Research grant / Funding (institution): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
3361 - Providing a nurse-led telephone intervention for patients treated with oral anticancer medication: symptom management and adherence monitoring
Presenter: Etienne Minvielle
Session: Poster Display session 3
Resources:
Abstract
3937 - Chronological evaluation of health-related quality of life and physical symptoms in postoperative pancreatic cancer patients up to 12 months
Presenter: Naoko Sato
Session: Poster Display session 3
Resources:
Abstract
5620 - Understanding the patients’ Experiences of Radiation Therapy: A Qualitative Study on Prostate Cancer Patients
Presenter: Sakarias Johansson
Session: Poster Display session 3
Resources:
Abstract
1792 - Effect of Kegel exercises on prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy
Presenter: Aydan Uravylioglu
Session: Poster Display session 3
Resources:
Abstract
2169 - The Meaning of Responsibility – a Secondary Analysis of Patients and Caregivers Calls to an Oncology Emergency Telephone
Presenter: Heidi Jacobsen
Session: Poster Display session 3
Resources:
Abstract
4587 - Cognitive function changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Elif Dil
Session: Poster Display session 3
Resources:
Abstract
1981 - Prevention of dental complications in patients with multiple myeloma (MM) receiving bisphosphonates treatment
Presenter: CESCA PUIGMARTI
Session: Poster Display session 3
Resources:
Abstract
2725 - Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients.
Presenter: Marina Bosch - Damas
Session: Poster Display session 3
Resources:
Abstract
5112 - Symptomatic and toxicity management of cancer patients using a telephone support model led by the oncology nurse
Presenter: Gemma Simó
Session: Poster Display session 3
Resources:
Abstract
1365 - Symptom cluster of fatigue, sleep disturbance and depression and its impact on quality of life among Chinese breast cancer patients undergoing adjuvant chemotherapy: A cross-sectional study
Presenter: Xiaole HE
Session: Poster Display session 3
Resources:
Abstract